Stock Track | Zymeworks Soars on Upcoming Catalysts for Lead Drug Zanidatamab

Stock Track
2024-11-04

Zymeworks Inc. (ZYME) saw its shares surge by 5.05% on November 4, 2024, as investors anticipated two major upcoming catalysts for the company's lead drug candidate, Zanidatamab.

First, the U.S. Food and Drug Administration (FDA) has set a PDUFA date of November 29, 2024, for the potential approval of Zanidatamab in the treatment of patients with second-line biliary tract cancer. The drug has been granted Priority Review, indicating the FDA's recognition of its potential to address an unmet medical need.

Secondly, Zymeworks and its partners, Jazz Pharmaceuticals and BeiGene, are expecting to release progression-free survival data from the phase 3 HERIZON-GEA-01 study in the second quarter of 2025. This study is evaluating Zanidatamab in combination with chemotherapy, with or without the addition of tislelizumab, for the treatment of patients with first-line locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10